Progressive hypofractionated carbon‐ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials

201798 citationsJournal Articlehybrid Open Access

Authors

Goro Kasuya · National Institutes for Quantum Science and Technology

Hirotoshi Kato · Ono Clinic

Shigeo Yasuda · National Institutes for Quantum Science and Technology

Hiroshi Tsuji · National Institutes for Quantum Science and Technology

Shigeru Yamada · National Institutes for Quantum Science and Technology

Yasuo Haruyama · Dokkyo Medical University

Gén Kobashi

Abstract

The safety and efficacy of CIRT in 12, 8, and 4 fractions were confirmed, with 52.8 Gy (RBE) in 4 fractions established as the recommended treatment course for eligible HCC patients. Cancer 2017;123:3955-65. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver Disease and Transplantation Radiation Therapy and Dosimetry

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 123, Issue 20, pp. 3955-3965

DOI: 10.1002/cncr.30816

Field-Weighted Citation Impact: 5.05